Literature DB >> 23154867

Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation.

Ryan Carr, Spero R Cataland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23154867     DOI： 10.1007/s00277-012-1622-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  15 in total

1.  Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

Authors:  Roxanne Cofiell; Anjli Kukreja; Krystin Bedard; Yan Yan; Angela P Mickle; Masayo Ogawa; Camille L Bedrosian; Susan J Faas
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 2.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

3.  Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Authors:  C Wehling; O Amon; M Bommer; B Hoppe; K Kentouche; G Schalk; R Weimer; M Wiesener; B Hohenstein; B Tönshoff; R Büscher; H Fehrenbach; Ö-N Gök; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2016-11-25       Impact factor: 4.330

4.  Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.

Authors:  Christoph Licht; Larry A Greenbaum; Petra Muus; Sunil Babu; Camille L Bedrosian; David J Cohen; Yahsou Delmas; Kenneth Douglas; Richard R Furman; Osama A Gaber; Timothy Goodship; Maria Herthelius; Maryvonne Hourmant; Christophe M Legendre; Giuseppe Remuzzi; Neil Sheerin; Antonella Trivelli; Chantal Loirat
Journal:  Kidney Int       Date:  2015-02-04       Impact factor: 10.612

Review 5.  Can eculizumab be discontinued in aHUS?: Case report and review of the literature.

Authors:  Tuncay Sahutoglu; Taner Basturk; Tamer Sakaci; Yener Koc; Elbis Ahbap; Mustafa Sevinc; Ekrem Kara; Cuneyt Akgol; Feyza Bayraktar Caglayan; Abdulkadir Unsal; Mohamed R Daha
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 6.  A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome.

Authors:  Borja Quiroga; Alberto de Lorenzo; Cristina Vega; Fernando de Alvaro
Journal:  Am J Case Rep       Date:  2016-12-15

7.  Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.

Authors:  Manuel Macia; Fernando de Alvaro Moreno; Tina Dutt; Ingela Fehrman; Karine Hadaya; Christoph Gasteyger; Nils Heyne
Journal:  Clin Kidney J       Date:  2016-12-22

Review 8.  Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

Authors:  Arif Asif; Ali Nayer; Christian S Haas
Journal:  J Nephrol       Date:  2016-11-15       Impact factor: 3.902

Review 9.  Complement therapy in atypical haemolytic uraemic syndrome (aHUS).

Authors:  Edwin K S Wong; Tim H J Goodship; David Kavanagh
Journal:  Mol Immunol       Date:  2013-06-28       Impact factor: 4.174

Review 10.  Critical appraisal of eculizumab for atypical hemolytic uremic syndrome.

Authors:  Lilian M Pereira Palma; Craig B Langman
Journal:  J Blood Med       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.